Yahoo Finance

• Q4 2024 Revenue: $164,000, down from $299,000 in Q4 2023.

• Full Year 2024 Revenue: $515,000, down from $11 million in 2023.

• Q4 2024 Cost of Revenue: $272,000, down from $773,000 in Q4 2023.

• Full Year 2024 Cost of Revenue: $1.6 million, down from $2 million in 2023.

• Q4 2024 Gross Loss: $108,000, compared to $474,000 in Q4 2023.

• Full Year 2024 Gross Loss: $1.1 million, compared to a gross profit of $9 million in 2023.

• Q4 2024 Operating Expenses: $3.9 million, down from $4.6 million in Q4 2023.

• Full Year 2024 Operating Expenses: $16.1 million, down from $16.5 million in 2023.

• Q4 2024 Net Loss: $3.9 million or $0.34 per share, compared to $4.7 million or $0.41 per share in Q4 2023.

• Full Year 2024 Net Loss: $16.6 million or $1.45 per share, compared to $7 million or $0.62 per share in 2023.

• Cash and Cash Equivalents (Dec 31, 2024): $11.9 million.

• Cash Used in Operating Activities (2024): $14.1 million, compared to $2.8 million in 2023.

• Cash Used in Investing Activities (2024): $539,000, compared to $1.2 million provided in 2023.

• Cash Provided by Financing Activities (2024): $9,000, compared to $1.1 million in 2023.

• Warning! GuruFocus has detected 4 Warning Signs with CLGN.

Release Date: March 26, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is advancing its proprietary photocurable dermal filler, which is in the preclinical phase and targets a market valued at approximately $6.3 billion with a 10% compound annual growth rate.

• The company has received positive feedback from thought leaders in aesthetic medicine regarding its photocurable dermal filler, suggesting it could be a game changer for facial plastic surgery.

• CollPlant's collaboration with AbbVie is progressing, with AbbVie collecting data from clinical trials and a recent $2 million payment received by CollPlant following a development achievement.

• The regenerative breast implant program is showing promising preclinical results, with successful tissue integration and vascularization observed in one study arm.

• CollPlant's recombinant human collagen technology is in demand, with ongoing discussions with various companies interested in accessing this technology.

Negative Points

• CollPlant Biotechnologies Ltd (NASDAQ:CLGN) reported a significant decrease in GAAP revenues for 2024, with $515,000 compared to $11 million in 2023, primarily due to a $10 million milestone payment from AbbVie in 2023.

• The company experienced a GAAP gross loss of $1.1 million for the year ended December 31, 2024, compared to a gross profit of $9 million in 2023.

• GAAP net loss for 2024 was $16.6 million, significantly higher than the $7 million net loss in 2023, attributed to the absence of a large milestone payment received in the previous year.

• Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, indicating higher operational expenses.

• The company's cash runway is expected to last only until the second quarter of 2026, raising concerns about long-term financial sustainability without additional revenue streams or partnerships.